Boris Gurevich, MD
Internal Medicine · Northbrook, ILNPI 1902877129
Payments from drug & device makers
Across 296 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$792
- Pfizer$540
- Johnson & Johnson$356
- Amarin Pharma, Inc.$349
- Lilly USA, LLC$293
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$220
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,955100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $792 |
| Pfizer | 25 | $540 |
| Johnson & Johnson(2 entities) | 17 | $356 |
| Amarin Pharma, Inc. | 18 | $349 |
| Lilly USA, LLC | 18 | $293 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $220 |
| AstraZeneca | 13 | $218 |
| Novartis | 12 | $209 |
| Novo Nordisk | 10 | $202 |
| E.r. Squibb & Sons, L.L.C. | 12 | $195 |
| Scilex Pharmaceuticals Inc. | 10 | $194 |
| Sunovion Pharmaceuticals Inc. | 13 | $172 |
| Boehringer Ingelheim | 7 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $109 |
| Astellas Pharma US Inc | 4 | $86 |
| Merck | 5 | $81 |
| Vivus LLC | 5 | $80 |
| Sanofi-aventis U.S. LLC | 5 | $72 |
| GSK | 4 | $70 |
| Abbott | 3 | $61 |
| Corcept Therapeutics | 3 | $54 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| Fidia Pharma USA Inc. | 3 | $43 |
| Sanofi Pasteur Inc. | 2 | $42 |
| Exact Sciences | 2 | $41 |
| IBSA Pharma Inc. | 2 | $35 |
| Amgen | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Mannkind Corporation | 2 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Bioventus LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,971 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 474 | $333,737 |
| CreonLipase/Protease/Amylase | 100 | $102,054 |
| LinzessLinaclotide | 119 | $60,874 |
| TradjentaLinagliptin | 79 | $48,793 |
| JardianceEmpagliflozin | 53 | $46,226 |
| ZenpepLipase/Protease/Amylase | 52 | $43,867 |
| MyrbetriqMirabegron | 82 | $33,777 |
| JanuviaSitagliptin Phosphate | 49 | $33,248 |
| Lidocaine | 258 | $32,910 |
| VascepaIcosapent Ethyl | 76 | $29,805 |
| EntrestoSacubitril/Valsartan | 30 | $26,217 |
| XareltoRivaroxaban | 59 | $22,993 |
| TrulancePlecanatide | 40 | $22,351 |
| NexiumEsomeprazole Magnesium | 71 | $22,172 |
| NamzaricMemantine Hcl/Donepezil Hcl | 24 | $17,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $540 | $333,737474 claims |
| AbbVieCreon, Linzess, Namzaric, Synthroid | $792 | $186,824353 claims |
| Boehringer IngelheimTradjenta, Jardiance, Jentadueto Xr, Combivent Respimat | $135 | $108,400158 claims |
| MerckJanuvia, Janumet Xr | $81 | $43,88866 claims |
| Astellas Pharma US IncMyrbetriq | $86 | $33,77782 claims |
| NovartisEntresto | $209 | $26,21730 claims |
| AstraZenecaNexium, Crestor | $218 | $25,62783 claims |
| Johnson & JohnsonXarelto | $356 | $22,99359 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $220 | $22,35140 claims |
| GSKTrelegy Ellipta | $70 | $11,83218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $109 | $5,58711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Northbrook
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.